Home » Stocks » IMVT

Immunovant, Inc. (IMVT)

Stock Price: $15.42 USD -0.46 (-2.90%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $15.25 -0.17 (-1.10%) Apr 16, 6:33 PM
Market Cap 1.51B
Revenue (ttm) n/a
Net Income (ttm) -99.82M
Shares Out 97.97M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $15.42
Previous Close $15.88
Change ($) -0.46
Change (%) -2.90%
Day's Open 15.90
Day's Range 15.25 - 16.08
Day's Volume 567,913
52-Week Range 11.80 - 53.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

New York, New York--(Newsfile Corp. - April 18, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Co...

17 hours ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 16, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securi...

2 days ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...

2 days ago - Newsfile Corp

Atlanta, Georgia--(Newsfile Corp. - April 16, 2021) - Holzer & Holzer, LLC reminds investors who suffered financial losses on purchases of Immunovant, Inc. ("Immunovant" or the "Company") (NASDAQ: IMVT)...

2 days ago - Newsfile Corp

(Newsfile Corp. - April 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company...

2 days ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...

3 days ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $IMVT #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. (IMVT)

3 days ago - Business Wire

Los Angeles, California--(Newsfile Corp. - April 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Im...

3 days ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 14, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...

4 days ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 14, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Co...

4 days ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...

Other stocks mentioned: HSAC
5 days ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Im...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Immu...

Other stocks mentioned: HSAC
1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 9, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securit...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 7, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securit...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 7, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Immu...

Other stocks mentioned: HSAC
1 week ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Imm...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Immu...

Other stocks mentioned: HSAC
1 week ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (N...

1 week ago - Newsfile Corp

Covid-19 has put healthcare stocks in the limelight. These seven companies should be on your radar for the next pandemic.

Other stocks mentioned: DHR, GERM, GILD, HOLX, PFE, XLV
2 weeks ago - InvestorPlace

NEW YORK, April 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", ...

2 weeks ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...

3 weeks ago - Newsfile Corp

New York, New York--(Newsfile Corp. - March 25, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...

3 weeks ago - Newsfile Corp

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Los Angeles, California--(Newsfile Corp. - March 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (...

1 month ago - Newsfile Corp

NEW YORK, March 18, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class acti...

1 month ago - PRNewsWire

LOS ANGELES, March 17, 2021 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. ("Immunovant" or...

1 month ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - March 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - March 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (...

1 month ago - Newsfile Corp

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant",...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...

Other stocks mentioned: HSAC
1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - March 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - March 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (...

1 month ago - Newsfile Corp

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporati...

1 month ago - GlobeNewsWire

Immunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Roivant is a major stakeholder of Immunovant.

1 month ago - Zacks Investment Research

Los Angeles, California--(Newsfile Corp. - March 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (N...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - March 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Immu...

Other stocks mentioned: HSAC
1 month ago - Newsfile Corp

Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.

Other stocks mentioned: OPGN, ANCN
1 month ago - Benzinga

The company could get a buyout offer soon.

1 month ago - The Motley Fool

NEW YORK, March 07, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class ...

1 month ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, ...

1 month ago - Business Wire

NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of  Immunovant, Inc. f/k/a Health Sciences Acquisitions Corpo...

1 month ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Company")...

1 month ago - Business Wire

New York, New York--(Newsfile Corp. - March 4, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Com...

1 month ago - Newsfile Corp

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Immunovan...

1 month ago - GlobeNewsWire

BENSALEM, Pa.--(BUSINESS WIRE)---- $IMVT #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming April 20, 2021 deadline to file a lead plaintiff motion in the case filed on behal...

1 month ago - Business Wire

NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", ...

1 month ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - March 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. (N...

1 month ago - Newsfile Corp

NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class ...

1 month ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $IMVT #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 20, 2021 deadline to file a lead plaintiff motion in the class action fil...

1 month ago - Business Wire

About IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
IMVT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for Immunovant stock is "Strong Buy." The 12-month stock price forecast is 39.10, which is an increase of 153.57% from the latest price.

Price Target
$39.10
(153.57% upside)
Analyst Consensus: Strong Buy